24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
TREXLIEVA 500MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | TREXLIEVA 500MG |
|---|---|
| Composition | Methotrexate Injection 500mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
TREXLIEVA 500MG (Methotrexate Injection 500mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
TREXLIEVA 500 MG (Methotrexate Injection 500 mg) is a prescription medicine containing Methotrexate 500 mg, a widely used antimetabolite and antifolate agent utilized in the treatment of various cancers, autoimmune disorders, and certain severe inflammatory conditions. In oncology, Methotrexate plays a critical role in controlling the growth and spread of rapidly dividing cancer cells by interfering with DNA synthesis and cellular replication.
Methotrexate has been an important component of cancer treatment protocols for several decades and is used in hospitals and specialized oncology centers worldwide. It is commonly prescribed for cancers such as Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, Osteosarcoma, Breast Cancer, Head and Neck Cancer, and certain other malignancies. The medicine may also be used in selected non-cancer conditions under strict medical supervision.
Cancer cells multiply rapidly and require folic acid to produce DNA and grow. TREXLIEVA 500 MG works by blocking the enzyme Dihydrofolate Reductase (DHFR), which is essential for folic acid metabolism. By disrupting this process, Methotrexate prevents cancer cells from producing the DNA necessary for growth and division, ultimately leading to cell death.
TREXLIEVA 500 MG is commonly used for:
The medicine may be administered alone or in combination with other anticancer medicines depending on the type of cancer, disease stage, and treatment goals. High-dose Methotrexate therapy is often followed by specialized supportive care measures, including leucovorin rescue, to help reduce toxicity.
Manufactured under strict pharmaceutical quality standards, TREXLIEVA 500 MG is designed to provide consistent therapeutic performance, safety, and reliability. The injection should only be administered by qualified healthcare professionals experienced in oncology and chemotherapy treatment.
Patients receiving Methotrexate therapy typically require regular monitoring through blood tests, liver function assessments, kidney function evaluations, and routine clinical examinations to ensure safe and effective treatment.
Due to its proven efficacy and broad therapeutic applications, TREXLIEVA 500 MG remains an essential medicine in modern oncology and specialized medical care.
TREXLIEVA 500 MG (Methotrexate Injection 500 mg) is primarily used for the treatment of various cancers and specific medical conditions requiring antimetabolite therapy.
The medicine is widely used in leukemia treatment protocols to help control abnormal white blood cell growth.
Methotrexate may be prescribed as part of comprehensive lymphoma treatment plans.
The medicine plays an important role in certain treatment protocols for bone cancer.
TREXLIEVA may be included in selected chemotherapy regimens for breast cancer management.
Doctors may prescribe Methotrexate to help control tumor growth in specific cancers of the head and neck region.
The medicine is used in the treatment of trophoblastic tumors and related conditions.
Methotrexate is frequently administered alongside other anticancer medicines to improve treatment outcomes.
The medicine supports comprehensive cancer treatment strategies across multiple malignancies.
Methotrexate belongs to a class of medicines known as Antimetabolites and Antifolate Agents.
TREXLIEVA works by:
This mechanism helps control disease progression and improve cancer treatment outcomes.
Like all chemotherapy medicines, TREXLIEVA 500 MG may cause side effects in some patients. Side effects vary depending on dosage, treatment duration, and individual patient factors.
Patients may experience mild to moderate nausea during treatment.
Episodes of vomiting may occur following administration.
Weakness and tiredness are commonly reported.
Reduced appetite may affect nutritional intake.
Oral ulcers and mouth irritation may develop during therapy.
Digestive disturbances and loose stools may occur.
Temporary hair loss or thinning may develop in some patients.
Some individuals may experience skin-related reactions.
Methotrexate may reduce:
This may increase the risk of infections, anemia, and bleeding complications.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of TREXLIEVA 500 MG (Methotrexate Injection 500 mg) should always be determined by a qualified oncologist or healthcare professional.
Different cancers and medical conditions require different treatment schedules.
Dosage is commonly calculated according to body size.
Kidney health significantly influences Methotrexate dosing.
Patients with liver impairment may require special monitoring and dosage adjustments.
Doctors may modify therapy based on effectiveness and side effect management.
Before receiving treatment, patients should inform their doctor if they have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant women should not receive Methotrexate unless specifically recommended by a healthcare professional, as the medicine may cause serious harm to an unborn baby.
Breastfeeding should generally be avoided during treatment unless advised otherwise by a healthcare provider.
It is used for the treatment of various cancers including leukemia, lymphoma, osteosarcoma, breast cancer, and certain trophoblastic tumors.
Methotrexate is an antimetabolite and antifolate medicine that interferes with DNA synthesis and cancer cell growth.
Yes, it is a widely used chemotherapy medicine utilized in several oncology treatment protocols.
Yes, it is frequently included in combination chemotherapy regimens.
Yes, the medicine may lower white blood cells, red blood cells, and platelets, requiring regular monitoring.
Methotrexate is primarily eliminated through the kidneys, making kidney function monitoring essential for patient safety.
Yes, doctors typically recommend blood tests, liver function assessments, kidney evaluations, and routine medical examinations throughout therapy.
Yes, this medicine should only be administered by qualified healthcare professionals experienced in oncology, chemotherapy, and specialized cancer treatment.